Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

NCT07598396 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07598396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07598396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Recruiting
Start date
May 25, 2026
Completion date
August 31, 2028
Enrollment
30 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lupus, lupus nephritis, systemic lupus erythematosus